Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6465-6478

  Lajud, Shayanne A ^a   Nagda, Danish A ^a   Yamashita, Taku ^a,b   Zheng, Jun ^a   Tanaka, Nobuaki ^a,b   Abuzeid, Waleed M ^a,c   Civantos, Alyssa ^a   Bezpalko, Orysia ^a   O'Malley, Bert W ^a   Li, Daqing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 (4 METHYLPIPERAZIN 1 YLMETHYL)(2H) 7 OXA 1,2 DIAZABENZO[DE]ANTHRACEN 3 ONE; ADENOVIRUS VECTOR; MRN COMPLEX; NIBRIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG; BRCA1 PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; GPI 15427; MRE11A PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; NBN PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEAR PROTEIN; ORGANIC COMPOUND; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RAD50 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CELL DEATH; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; TELOMERE HOMEOSTASIS; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; GENOMIC INSTABILITY; HEAD AND NECK NEOPLASMS; METABOLISM; PATHOLOGY; SINGLE STRANDED DNA BREAK; SQUAMOUS CELL CARCINOMA; TELOMERE; TELOMERE SHORTENING; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; BRCA1 PROTEIN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA BREAKS, SINGLE-STRANDED; DNA REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; GENOMIC INSTABILITY; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; NUCLEAR PROTEINS; ORGANIC CHEMICALS; POLY(ADP-RIBOSE) POLYMERASES; TELOMERE; TELOMERE SHORTENING; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919769016     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0176     Document Type: Article

References (51)

1. Parkin DM, Bray F, Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. American Cancer Society. Cancer facts & figures. Atlanta, GA: American Cancer Society; 2013.
3. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010;15:994-1001.
4. Pinto AR, Li H, Nicholls C., Liu JP. Telomere protein complexes and interactions with telomerase in telomere maintenance. Front Biosci 2011;16:187-207.
5. Diotti R, Loayza D. Shelterin complex and associated factors at human telomeres. Nucleus 2011;2:119-35.
6. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98.
7. Audeh MW, Carmichael J, Penson R.T., Friedlander M., Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor ola-parib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
8. Tutt A, Robson M, Garber J.E., Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.
9. O'Shaughnessy J., Osborne C, Pippen J.E., Yoffe M., Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-14.
10. O'Shaughnessy J., Schwartzberg LS, Danso M.A., Rugo HS, Miller K, Yardley DA, et al A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29: 2011 (suppl; abstr 1007).
11. Bryant HE, Schultz N, Thomas H.D., Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7.
12. Farmer H, McCabe N, Lord C.J., Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
13. Gottipati P, Vischioni B, Schultz N., Solomons J, Bryant HE, Djureinovic T, et al. Poly(ADP-Ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010;70:5389-98.
14. Ying S, Hamdy FC, Helleday T. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res 2012;72:2814-21.
15. Abuzeid WM, Jiang X, Shi G., Wang H, Paulson D, Araki K., et al. Molecular disruption of RAD50 sensitizes human tumor cells to cis-platin-based chemotherapy. J Clin Invest 2009;119:1974-85.
16. Tran H, Shi G, Li G., Carney J, Omalleyjr B, Li D. Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer. Otolaryngol Head Neck Surg 2004;131:477-84.
17. O'Malley BW Jr, Li D, Carney J, Rhee J, Suntharalingam M. Molecular disruption of the MRN(95) complex induces radiation sensitivity in head and neck cancer. Laryngoscope 2003;113:1588-94.
18. Araki K, Yamashita T, Reddy N., Wang H, Abuzeid WM, Khan K, et al. Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer. Br J Cancer 2010;103: 1822-30.
19. Rhee JG, Li D, Suntharalingam M., Guo C, O'Malley BW Jr, Carney JP. Radiosensitization of head/neck squamous cell carcinoma by adenovirus-mediated expression of the Nbs1 protein. Int J Radiat Oncol Biol Phys 2007;67:273-8.
20. Khan K, Araki K, Wang D., Li G, Li X, Zhang J., et al. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 2010;32:381-91.
21. Zhong ZH, Jiang WQ, Cesare A.J., Neumann AA, Wadhwa R, Reddel RR. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J Biol Chem 2007;282:29314-22.
22. Wu Y, Xiao S, Zhu X-D. MRE11-RAD50-NBS1 and ATM function as co-mediators of TRF1 in telomere length control. Nat Struct Mol Biol 2007;14:832-40.
23. 2 phases in immortalized telomerase-negative cells. Implication of NBS1 in alternative lengthening of telomeres. J Biol Chem 2000;275:30618-22.
24. Zhu XD, Kuster B, Mann M., Petrini JH, de Lange T. Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nat Genet 2000;25:347-52.
25. Chang W. TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomeres. Genes Dev 2003;17:1328-33.
26. Ye JZ-S, deLange T. TIN2 isatankyrase 1PARP modulator in the TRF1 telomere length control complex. Nat Genet 2004;36:618-23.
27. Smith S, Giriat I, Schmitt A., de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998;282:1484-7.
28. Helma C, Uhl M. A public domain image-analysis program for the single-cell gel-electrophoresis (comet) assay. Mutat Res 2000;466: 9-15.
29. Henson JD, Cao Y, Huschtscha L.I., Chang AC, Au AY, Pickett HA, et al. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol 2009;27:1181-5.
30. Lovejoy CA, Li W, Reisenweber S., Thongthip S, Bruno J, de Lange T, et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012;8:e1002772.
31. Tuominen VJ, Ruotoistenmaki S, Viitanen A., Jumppanen M, Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 2010;12:R56.
32. Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 1992;356:356-8.
33. Caldecott KW. Single-strand break repair and genetic disease. Nat Rev Genet 2008;9:619-31.
34. Dantzer F, Ame JC, Schreiber V, Nakamura J., Menissier-de Murcia J, de Murcia G. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol 2006;409:493-510.
35. Schreiber V, Dantzer F, Ame J.C., de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7: 517-28.
36. Godon C, Cordelieres FP, Biard D, Giocanti N., Megnin-Chanet F, Hall J, et al. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res 2008;36:4454-64.
37. Kobayashi J, Tauchi H, Sakamoto S., Nakamura A, Morishima K, Matsuura S., et al. NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain. Curr Biol 2002;12:1846-51.
38. Uziel T, Lerenthal Y, Moyal L., Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003;22:5612-21.
39. Arnaudeau C, Helleday T, Jenssen D. The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells. J Mol Biol 1999;289:1231-8.
40. Graeser M, McCarthy A, Lord C.J., Savage K., Hills M, Salter J, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010;16:6159-68.
41. Schultz N, Lopez E, Saleh-Gohari N, Helleday T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 2003;31:4959-64.
42. Haber JE. DNA recombination: the replication connection. Trends Biochem Sci 1999;24:271-5.
43. van Steensel B., de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997;385:740-3.
44. Beneke S, Cohausz O, Malanga M., Boukamp P, Althaus F, Burkle A. Rapid regulation of telomere length is mediated by poly(ADP-ribose) polymerase-1. Nucleic Acids Res 2008;36:6309-17.
45. Forastiere AA, Trotti A, Pfister D.G., Grandis JR. Head and neck cancer: recent advances and new standards of care. J Clin Oncol 2006;24: 2603-5.
46. Kirn D, Hermiston T, McCormick F. ONYX-015: clinical data are encouraging. Nat Med 1998;4:1341-2.
47. Khuri FR, Nemunaitis J, Ganly I., Arseneau J, Tannock IF, Romel L, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluoro-uracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
48. Kirn DH. A phase II trial of intratumoral injection with a selectively replicating adenovirus (ONYX-015) in patients with recurrent, refractory squamouscell carcinoma of thehead andneck. MethodsMol Med 2000;35:559-74.
49. Nemunaitis J, Khuri F, Ganly I., Arseneau J, Posner M, Vokes E., et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-98.
50. Nemunaitis J. Head and neck cancer: response to p53-based therapeutics. Head Neck 2011;33:131-4.
51. Dupre A, Boyer-Chatenet L, Sattler R.M., Modi AP, Lee JH, Nicolette ML, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol 2008;4:119-25.